Research Funding Disparities

ME/CFS is one of the most underfunded diseases relative to its burden in the history of modern biomedical research. This underfunding is both a cause and a consequence of the controversies described in this chapter.

1 Historical Underfunding

NIH funding for ME/CFS remained below $10 million annually for most of the 2000s–2010s, despite an estimated disease burden of $17–24 billion in annual economic losses and approximately 1–2.5 million affected Americans. For comparison, multiple sclerosis (with a similar US prevalence) receives approximately $130 million annually, and HIV/AIDS (with a lower US prevalence) receives over $3 billion. The funding disparity per patient-year-of-disability is estimated at 10–100-fold. The causes of underfunding are interrelated:

  • Psychogenic classification: When ME/CFS was classified as primarily psychological, it fell outside the mandate of biomedical research institutes
  • Absence of a biomarker: Without a diagnostic test, ME/CFS lacked the β€œhard science” credentials that attract competitive grant funding
  • Stigma: Researchers reported that working on ME/CFS was professionally stigmatizing, discouraging junior investigators from entering the field
  • Small research workforce: Chronic underfunding created a small, isolated research community with limited capacity to generate the volume of publications needed to attract further fundingβ€”a vicious cycle
  • Patient invisibility: Housebound and bedbound patients are invisible to society, unable to participate in advocacy activities that drive research funding for other diseases A comparative analysis of NIH funding per patient-year across diseases places ME/CFS at the bottom tier, with a funding-to-burden ratio orders of magnitude below comparably disabling conditions (ME/CFS Science 2020a). The structural analysis by mecfsscience.org identifies the self-reinforcing nature of the underfunding cycle: psychogenic classification reduces funding, reduced funding limits biomedical discoveries, and the absence of discoveries reinforces the psychogenic framing (ME/CFS Science 2020b). Breaking this cycle requires deliberate institutional intervention rather than reliance on organic funding growth

2 Recent Improvements

ME/CFS research funding has increased modestly since 2015:

  • NIH funding rose from approximately $5 million (2014) to a peak of approximately $15–18 million (2023), driven partly by the creation of ME/CFS research centers and the NIH intramural study
  • However, this trend has reversed: 2024 funding fell to $10.1 million across 25 projects (less than 0.03% of the total NIH budget), and 2025 funding declined further to $7.4 million across just 18 projectsβ€”a 7% year-on-year decrease (ME/CFS Science 2024) (ME/CFS Science 2025). This decline is occurring while European countries are increasing ME/CFS research investment (ME/CFS Science 2025)
  • The long COVID pandemic generated spillover funding for ME/CFS through overlap studies, but dedicated ME/CFS funding appears to be shrinking as long COVID research absorbs available resources
  • Private foundations (Open Medicine Foundation, Solve ME/CFS Initiative, ME Research UK) have contributed substantial additional funding and research infrastructure
  • International initiatives (European ME/CFS research network, DecodeME in the UK) have expanded the research base beyond the US

3 Remaining Gaps

Despite improvements, critical funding gaps persist:

  • Clinical trials: No large, multi-center, biomarker-stratified clinical trial has been funded for ME/CFS. The trials that exist are small, single-center, and investigator-initiated
  • Severe patients: Research on severe and very severe ME/CFS is virtually non-existent because these patients cannot travel to research centers. Home-based and remote research protocols require dedicated funding
  • Longitudinal cohorts: No prospective cohort study with \(\geq\) 20-year follow-up exists, leaving fundamental questions about natural history and mortality unanswered
  • Training pipeline: The ME/CFS research workforce remains critically small. Dedicated training grants and career development awards are needed to attract new investigators
  • Funding parity: Even at current levels, ME/CFS receives less than 10% of the per-patient funding of comparable chronic diseases. Reaching funding parity would require a 5–10-fold increase

References

ME/CFS Science. 2020a. β€œDisease Funding Comparison: ME/CFS.” 2020. https://mecfsscience.org/disease-funding-comparison-me-cfs/.
β€”β€”β€”. 2020b. β€œWhy Is ME/CFS Getting so Little Research Funding?” 2020. https://mecfsscience.org/why-is-me-cfs-getting-so-little-research-funding/.
β€”β€”β€”. 2024. β€œNIH Funding for ME/CFS in 2024.” 2024. https://mecfsscience.org/nih-funding-for-me-cfs-in-2024/.
β€”β€”β€”. 2025. β€œNIH Funding for ME/CFS Keeps Falling.” 2025. https://mecfsscience.org/nih-funding-for-me-cfs-keeps-falling/.